



14th ANNUAL MEETING OF THE LUPUS ACADEMY Meeting Book

Annual Meeting (Berlin and Online)
9–11th October 2025

Welcome

Dear Friends and Colleagues,

Welcome to the 14th Annual Meeting of the Lupus Academy!

We are delighted to have you join us in Berlin for three days of the latest advancements in lupus education. This year's meeting is designed to enhance your knowledge and provide valuable clinical and research insights to improve outcomes for patients with lupus.

The Lupus Academy is committed to delivering high-quality education, offering new and practical tools to improve patient care through live meetings and online resources. This year's programme features a dynamic mix of cutting-edge scientific presentations on the latest lupus research, interactive workshops focused on clinical practice, and networking opportunities with leading experts, clinicians and scientists from around the world. The meeting will take place from 9–11th October, during which you can participate in plenaries, workshops, poster sessions, and much more. Selected sessions have been chosen for live online broadcast and post-meeting recordings of all presentations will be available to ensure you will not miss any part of the event.

Developed with the support of our renowned international steering committee, this year's meeting programme promises to spark new ideas, enrich your practice, and ignite your passion for improving lupus management. We look forward to your participation, whether in-person or virtually, at the 14th Annual Meeting of the Lupus Academy.

The Lupus Academy co-Chairs

Thomas Dörner

Lupus Academy co-Chair (2025)

Maria Dall'Era

Lupus Academy co-Chair (2025)

The Lupus Academy Steering Committee

Zahir Amoura

Eloisa Bonfá

Ricard Cervera

Maria Dall'Era

Andrea Doria

Thomas Dörner

David Isenberg

Richard Furie

**Bernardo
Pons-Estel**

Sandra Navarra

Murray Urowitz

**Ronald van
Vollenhoven**

[†]The Lupus Academy is a long-term initiative dedicated to improving patient outcomes in SLE through an interactive educational forum dedicated to sharing best clinical practice through the dissemination and discussion of clinical and basic scientific research about SLE and allied diseases.



To participate in polling questions and to post your questions to the faculty, download the interactive voting app [Join at [slido.com #678487](https://slido.com/join/678487)]

Meeting Learning Objectives

The Lupus Academy's 14th Annual Meeting programme will focus on current key issues in lupus clinical practice and is designed to facilitate improved understanding of these issues and their management through both presentations and shared clinical insights through case study workshops. At the end of the programme delegates should be able to:

- Discuss recent advances in the pathogenesis and management of lupus nephritis, including ACR 2025 guideline, EULAR recommendations, biomarkers and nephroprotective therapies
- Explain why measuring and controlling disease activity at an early stage are critical for improving outcomes in patients with lupus
- Describe outcome considerations for the cardio-rheumatologist's perspective
- Explain what's new in research about diet and the microbiome in SLE
- Discuss the diagnostic challenges between systemic immune-mediated diseases
- Describe and share clinical experience of managing cardiovascular disease, hematological problems, family planning and pregnancy, skin disease, and joint disease
- Discuss attainment of remission from the rheumatologist's, nephrologist's, and dermatologist's perspectives
- Describe what is needed to adequately assess joint disease in lupus clinical trials
- Discuss recent insights from innate immunity and their implications for the understanding and management of SLE
- Demonstrate understanding of emerging treatment concepts, including glucocorticoid dosing, CD40/L costimulation blockade and cytokine inhibition, in SLE
- Explain the current evidence for B-cell depletion in SLE with respect to novel therapies, including anti-CD20, T-cell engager and CAR-T therapy

Abstracts of the presentations are published in the official journal of the 14th Annual Meeting:



Continuing Medical Education



The 14th Annual Meeting of the Lupus Academy has been planned and implemented in accordance with the accreditation requirements of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Siyemi Learning and the Lupus Academy. Siyemi Learning is accredited by the ACCME to provide continuing medical education for physicians.

Siyemi Learning designates this live activity for a maximum of 14 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Claiming Your CME Certificate

PLEASE NOTE: You will be able to claim your CME certificate from 15th October 2025.

Go to LupusCME.org to complete the evaluation and claim your CME Certificate of Attendance.

Sign in with the email address you used to register for the meeting, if it is the first time you are entering the site you will be asked to register.

Disclosures

Financial disclosures of the speakers can be found with their biography on the meeting website. Neither the Lupus Academy planning staff, Julian Ball, Nicole Elzebroek, Eugene Pozniak, nor staff at Siyemi Learning, have any relevant financial relationships to disclose.

Commercial Support

This activity is supported by an independent educational grant from GSK.



Contents

14TH ANNUAL MEETING OF THE LUPUS ACADEMY

9–11th October 2025,

Berlin, Germany

Catch-up Content Available Online Until 31st December 2025

<http://www.lupus-academy.org/>

Programme	8
Biographies	12
Notes	32

Programme

Thursday 9th October 2025

INDUSTRY-SPONSORED SYMPOSIUM*

CEST (UTC +2 Berlin) 11:00–12:00 hours

11:00–12:00	Industry-Sponsored Symposium by AstraZeneca Prioritising remission and organ damage prevention in SLE care: expert perspectives from the clinic	<i>Tobias Alexander (Germany)</i> <i>Marta Mosca (Italy)</i>
12:00–13:00	Lunch	

*This non-accredited industry-sponsored symposium is not part of the accredited CME programme.

OPENING SESSION (HYBRID)

CEST (UTC +2 Berlin) 13:00–15:00 hours

PST (UTC +8 Manila) 19:00–21:00 hours

EDT (UTC -4 New York) 7:00 AM – 09:00 AM

Moderators: Maria Dall'Era (USA) & Thomas Dörner (Germany)		
13:00	Opening Remarks	<i>Thomas Dörner (Germany)</i>
	Recent Advances in the Pathogenesis and Management of Lupus Nephritis	
13:10	2024 ACR lupus nephritis guidelines	<i>Maria Dall'Era (USA)</i>
13:30	EULAR recommendations for lupus nephritis	<i>Antonis Fanouriakis (Greece)</i>
13:50	Update on urinary biomarkers in lupus nephritis	<i>Andrea Fava (USA)</i>
14:10	Nephroprotective therapies: Which one and when to start? (SGLT2i, GLP-1, MRA)	<i>Eva Schrezenmeier (Germany)</i>
14:30	Q&A and Panel Discussion	
15:00–15:30	Break and Poster Viewing	

PLENARY I: THE ULTIMATE GOALS “OUTCOME, OUTCOME, OUTCOME...!”

CEST (UTC +2 Berlin) 15:30–17:00 hours

Moderators: Murray Urowitz (Canada) & Ronald van Vollenhoven (Netherlands)		
15:30	How are we doing in controlling SLE activity?	<i>Sandra Navarra (Philippines)</i>
15:50	Mechanisms of glucocorticoids revisited: The dose makes the poison (?)	<i>Gerhard Krönke (Germany)</i>
16:10	Cardiovascular outcomes in SLE: A cardio-rheumatologist's perspective	<i>Brittany Weber (USA)</i>
16:30	Q&A and Panel Discussion	

KEYNOTES: SLE IN THE 21ST CENTURY

CEST (UTC +2 Berlin) 17:00–18:30 hours

Moderators: Bernardo Pons Estel & Maria Dall'Era (USA)		
17:00	New insights into the gut microbiome and lupus pathogenesis	<i>Gregg Silverman (USA)</i>
17:30	Q&A and Panel Discussion	
17:45	Insights into inflammatory CNS diseases: Navigating diagnostic challenges between systemic immune-mediated diseases and multiple sclerosis	<i>Thomas Skripuletz (Germany)</i>
18:15	Q&A and Panel Discussion	
18:30–20:00	Networking Walking Dinner and Poster Viewing	

Friday 10th October 2025

INDUSTRY-SPONSORED SYMPOSIUM*

CEST (UTC +2 Berlin) 07:30–08:30 hours

07:30–08:30	Industry-Sponsored Symposium by Bristol Myers Squibb Emerging concepts in management and treatment of Sjögren's Disease	<i>Wan-Fai Ng (UK)</i> <i>Gweny Verstappen (Netherlands)</i> <i>Christina Gebhardt (Germany)</i>
08:30–09:00	Break	

*This non-accredited industry-sponsored symposium is not part of the accredited CME programme.

INTERACTIVE CASE STUDY WORKSHOPS

CEST (UTC +2 Berlin) 09:00–10:30 hours

Moderator: Maria Dall'Era (USA)		
09:00	Managing lupus and cardiovascular disease	<i>Murray Urowitz (Canada) & Mike Nurmohamed (Netherlands)</i>
Moderator: Bernardo Pons Estel (Argentina)		
09:00	Managing haematologic manifestations in SLE	<i>Sandra Navarra (Philippines) & George Bertias (Greece)</i>
Moderator: Angela Tincani (Italy)		
09:00	Family planning and pregnancy in SLE	<i>Ian Giles (UK) & Ana-Luisa Stefanski (Germany)</i>
Moderator: Andrea Doria (Italy)		
09:00	Managing lupus skin manifestations	<i>Annegret Kuhn (Germany) & Victoria Werth (USA)</i>
Moderator: Richard Furie (USA)		
09:00	Assessing and managing lupus arthritis	<i>Anca Askanase (USA) & Alexandre Voskuyl (Netherlands)</i>
10:30–11:00	Break and Poster Viewing	

PRIME TIME SESSION (HYBRID): NEW GOALS IN SLE - WHAT DOES REMISSION LOOK LIKE?

CEST (UTC +2 Berlin) 11:00–13:00 hours

PST (UTC +8 Manila) 17:00–19:00 hours

EDT (UTC -4 New York) 5:00 AM – 07:00 AM

Moderators: Richard Furie (USA) & Andrea Doria (Italy)		
11:00	LLDAS and DORIS remission redefined or refined: The rheumatologist's perspective	<i>Ronald van Vollenhoven (Netherlands)</i>
11:25	Remission in lupus nephritis: The nephrologist's perspective	<i>Onno Teng (Netherlands)</i>
11:50	Lupus skin and remission: The dermatologist's perspective	<i>Victoria Werth (USA)</i>
12:10	Lupus arthritis: Adequate joint assessment in SLE trials	<i>Ed Vital (UK)</i>
12:35	Q&A and Panel Discussion	
13:00–14:00	Lunch and Poster Viewing	

Programme

KEYNOTE EMERGING PATHOGENIC INSIGHTS

CEST (UTC +2 Berlin) 14:00–14:30 hours

Moderators: Sandra Navarra (Philippines) & Maria Dall'Era (USA)		
14:00	Recent insights from innate immunity: Implications for SLE	<i>Eicke Latz (Germany)</i>
	Q&A	

PLENARY II: EMERGING TREATMENT CONCEPTS

CEST (UTC +2 Berlin) 14:30–16:00 hours

Moderators: Sandra Navarra (Philippines) & Bernardo Pons Estel (Argentina)		
14:30	Belimumab versus anifrolumab in non-renal SLE: Which drug for which patient?	<i>Andrea Doria (Italy)</i>
14:55	Co-stimulation blockade of CD40/CD40L in SLE and beyond	<i>Andrea Fava (USA)</i>
15:20	News and views: Exciting new approaches in therapy, double-hit therapies, JAK inhibitors	<i>Murray Urowitz (Canada)</i>
15:45	Q&A and Panel Discussion	
16:00–16:30	Break and Poster Viewing	

INTERACTIVE CASE STUDY WORKSHOPS

CEST (UTC +2 Berlin) 16:30–18:00 hours

Moderator: Maria Dall'Era (USA)		
16:30	Managing lupus and cardiovascular disease	<i>Murray Urowitz (Canada) & Mike Nurmohamed (Netherlands)</i>
Moderator: Bernardo Pons Estel (Argentina)		
16:30	Managing haematologic manifestations in SLE	<i>Sandra Navarra (Philippines) & George Bertsias (Greece)</i>
Moderator: Angela Tincani (Italy)		
16:30	Family planning and pregnancy in SLE	<i>Ian Giles (UK) & Ana-Luisa Stefanski (Germany)</i>
Moderator: Andrea Doria (Italy)		
16:30	Managing lupus skin manifestations	<i>Annegret Kuhn (Germany) & Victoria Werth (USA)</i>
Moderator: Richard Furie (USA)		
16:30	Assessing and managing lupus arthritis	<i>Anca Askanase (USA) & Alexandre Voskuyl (Netherlands)</i>
18:00	Session Close and Poster Viewing	

Saturday 11th October 2025

INDUSTRY-SPONSORED SYMPOSIUM*

CEST (UTC +2 Berlin) 08:00–09:00 hours

08:00–09:00	Industry-Sponsored Symposium by GSK Evidence to action: organ protection and kidney function preservation in lupus care	<i>Andrea Doria (Italy)</i> <i>Onno Teng (Netherlands)</i>
09:00–09:30	Break	

*This non-accredited industry-sponsored symposium is not part of the accredited CME programme.

THIEVES MARKET AND POSTER PRESENTATIONS*

CEST (UTC +2 Berlin) 09:30–10:30 hours

Moderators: Thomas Dörner (Germany) & Ricard Cervera (Spain)		
Thieves' Market		
09:30	A gut feeling: When lupus hides behind abdominal pain	<i>Irum Awan (UK)</i>
09:40	The butterfly effect: The different faces of systemic lupus erythematosus, all in one child	<i>Afroditi Barmpakou (UK)</i>
Posters		
09:50	The HERACLES trial - A novel topical anti-inflammatory therapeutic targeting toll-like receptors 7 and 8 in cutaneous lupus erythematosus	<i>Olivier Laczka (Australia)</i>
10:00	Piggybac transposon-mediated CD-19 CART-cell therapy in refractory systemic lupus erythematosus	<i>Wonngarm Kittanamongkolchai (Thailand)</i>
10:10	When lupus attacks the brain: Insights from 38 neuropsychiatric cases	<i>Naoual Dalhi (Morocco)</i>
10:20	Soluble checkpoint molecules as predictive biomarker for disease activity and long-term outcome in SLE	<i>Léa-Sophie Drevetton (Germany)</i>
10:30	Thieves Market and Poster Awards	<i>All</i>
10:35–11:00	Break and Poster Viewing	

*Thieves' market and Poster Session are not part of the accredited CME total.
More Posters are available at lupus-academy.org

PLENARY III: B-CELL DEPLETION IN SLE - PAST, PRESENT AND FUTURE (HYBRID)

CEST (UTC +2 Berlin) 11:00–13:00 hours

PST (UTC +8 Manila) 17:00–19:00 hours

EDT (UTC -4 New York) 5:00 AM – 7:00 AM

Moderators: Thomas Dörner (Germany) & Ronald van Vollenhoven (Netherlands)		
11:00	Historical perspectives on B-cell depletion in SLE	<i>David Isenberg (UK)</i>
11:25	Anti-CD20 therapy: Where are we today?	<i>Richard Furie (USA)</i>
11:50	T-cell engager experience in SLE	<i>Gerhard Krönke (Germany)</i>
12:15	CAR-T: Emerging options	<i>Georg Schett (Germany)</i>
12:40	Q&A and Panel Discussion	
13:00	Concluding Remarks and Meeting Close	

Biographies



Professor Zahir Amoura, MD, MSc
Pitié-Salpêtrière Hospital, Paris, France

Zahir Amoura has been a leading figure in the field of systemic lupus erythematosus (SLE) for over two decades. Since 2003, he has served as Professor of Internal Medicine at the French National Reference Center for SLE at the prestigious Pitié-Salpêtrière Hospital in Paris, where he was also appointed as Head of the Department of Internal Medicine in 2009.

Professor Amoura's distinguished academic journey includes completing his Paris Hospital Medical Internship in 1988 and earning a Master's degree in immunopharmacology in 1989. He was awarded his MD with a silver medal in 1993, followed by his qualifying certification in internal medicine in 1994. In 1995, he joined the Department of Internal Medicine at Pitié-Salpêtrière Hospital as a Senior Lecturer and Senior Practitioner, building the foundation for his current prominent roles.

Professor Amoura's significant contributions to the understanding of SLE are underscored by his extensive research portfolio, comprising over 697 peer-reviewed publications. Notably, 323 of these publications specifically focus on the intricate immunopathological features of lupus.

Financial Disclosures

Consultant/Advisor:

AstraZeneca; GSK; Merck;
Novartis; Roche.

All of the relevant financial relationships listed for this individual have been mitigated.



Professor Anca D. Askanase, MD, MPH
Columbia University Lupus Center, New York, USA

Anca Askanase is Professor of Medicine, Founder and Director of the Columbia University Lupus Center (CUIMC), and Associate Chair for Clinical Trials Department of Medicine. She is a clinician, diagnostician, and researcher specialising in complex systemic lupus erythematosus (SLE).

Professor Askanase trained as a rheumatologist at New York University (NYU) where she remained for more than 15 years on faculty, directing clinical trials, training fellows and residents, and treating challenging cases of SLE at NYU's prestigious hospitals.

Her research in lupus encompasses multiple areas involving lupus epidemiology, including cohort and registry studies, to allow for in-depth characterisation of disease phenotype and comorbidities; outcomes research to identify biomarkers and develop objective and novel instruments to more accurately diagnose lupus, track disease activity, and define treatment response; and clinical trials to increase treatment options.

Much of Professor Askanase's research is conducted in collaboration with national and international lupus researchers. She founded the CUIMC Lupus Cohort, and is an active participant in the Systemic Lupus Collaborating Clinics (SLICC) and The Lupus Clinical Trials Network (LuCIN) SLE registries.

Professor Askanase's ongoing projects include the use of optical imaging to evaluate lupus arthritis, development of virtual lupus disease activity measures for use in clinical research, and lupus outreach to disparate populations in New York City.

Financial Disclosures

Consultant/Advisor:

AstraZeneca; Bristol Myers
Squibb; Cabaletta; GSK;
Novartis.

All of the relevant financial relationships listed for this individual have been mitigated.



Professor George Bertsias, MD, PhD
University of Crete, Medical School, Greece

George Bertsias graduated from the University of Crete School of Medicine (UoCSM). Following his internship, he pursued graduate studies earning his MSc and PhD in immunology/autoimmunity. He conducted post-doctoral research at the National Human Genome Research Institute, National Institutes of Health (NIH/NHGRI), and subsequently received training in Rheumatology and Clinical Immunology.

Professor Bertsias has a keen scientific interest in systemic autoimmunity, particularly systemic lupus erythematosus (SLE). He is an active member of the European Alliance of Associations for Rheumatology (EULAR) study group on SLE, where he coordinates the development of clinical recommendations for the diagnosis and treatment of patients with SLE. Professor Bertsias has been a faculty member in Rheumatology-Clinical Immunology and a Principal Investigator at the Laboratory of Autoimmunity and Inflammation, UoCSM, since 2014. He has successfully launched a specialised clinic focused on connective tissue diseases and SLE, which serves as a referral center for the island of Crete. He also manages the Cretan Lupus and Preclinical Lupus Registry, which contains data on over 500 patients with SLE.

Professor Bertsias' research focuses on the early diagnosis and outcomes of SLE, including the response to novel therapeutic and biological agents. In addition, Professor Bertsias' laboratory explores the role of genetic, epigenetic, and metabolic factors in driving the aberrant activation of immune cells in SLE.

Financial Disclosures

Consultant/Advisor:

Argenx; AstraZeneca; Bristol Myers Squibb.

Research Grants:

AstraZeneca; GSK; MSD.

Speaker:

AbbVie; AstraZeneca; GSK; Otsuka; Pfizer.

All of the relevant financial relationships listed for this individual have been mitigated.



Professor Ricard Cervera, MD, PhD
Hospital Clinic Barcelona, Catalonia, Spain

Ricard Cervera is co-Founder and Head of the Department of Autoimmune Diseases at Hospital Clinic Barcelona. He is also leader of the Research Group on Systemic Autoimmune Diseases at the August Pi i Sunyer Biomedical Research Institute (IDIBAPS) and Professor at the University of Barcelona, where he coordinates the Master's Course on Autoimmune Diseases, and serves as Vice Dean of Academic Affairs and International Relations at its Faculty of Medicine and Health Sciences. Professor Cervera qualified in medicine in 1983 from University of Barcelona, and received his PhD in 1988 for his thesis on anticardiolipin antibodies. He spent 2 years at the Lupus Research Unit at The Rayne Institute, St Thomas' Hospital, London, UK.

Professor Cervera is an Associate Editor of the journals Lupus Science & Medicine and European Journal of Internal Medicine and is on the Editorial Boards of 20 medical journals. He is a Founding Member of the Board of the European Lupus Society (SLEuro) and past-coordinator of the European Working Party on Systemic Lupus Erythematosus (Euro-Lupus Group) (1991–2008) and of the European Forum on Antiphospholipid Antibodies (2009–2017). He is Chairman of the Medical Advisory Board of the Catalan Association of Lupus Patients and Medical Advisor to Lupus Europe. He chaired the 6th, 8th and 11th International Congresses on Autoimmunity, the 1st, 2nd and 5th Latin-American Congresses on Autoimmunity, the 5th Meeting of the European Forum on Antiphospholipid Antibodies and the 8th European Lupus Congress.

Professor Cervera's research interests include clinical and epidemiological aspects of systemic autoimmune diseases, particularly systemic lupus erythematosus and antiphospholipid syndrome, with special focus on its 'catastrophic' variant. He has presented over 1000 invited lectures and published more than 1000 scientific papers (H-index: 103), including original articles in the New England Journal of Medicine, The Lancet, Annals of the Rheumatic Diseases, Arthritis & Rheumatism, American Journal of Medicine and Medicine (Baltimore). He is co-Editor of 50 books, including 'The Antiphospholipid Syndrome', 'Vascular Manifestations of Systemic Autoimmune Diseases' and 'Diagnostic Criteria in Autoimmune Diseases'.

Financial Disclosures

Consultant/Advisor:

AstraZeneca; GSK.

Speaker:

Rubió; Thermo Fisher Scientific; Werfen.

All of the relevant financial relationships listed for this individual have been mitigated.

Biographies



Professor Maria Dall'Era, MD
University of California, San Francisco, USA

Maria Dall'Era is the Jean S. Engleman Distinguished Professor of Medicine and Chief of the Division of Rheumatology at the University of California, San Francisco. She is the Director of the University of California, San Francisco (UCSF) Rheumatology Clinical Research Center and Lupus Center.

Professor Dall'Era serves as Co-chair of the Lupus Therapeutics Board of Directors and is on the Steering Committees of the Lupus Academy, Lupus Forum, and the Lupus 21st Century annual conference. She also serves on the Research Committee of the Lupus Accelerating Breakthroughs Consortium. She holds the position of Principal Investigator (PI) for the Centers for Disease Control and Prevention-funded California Lupus Epidemiology Study, a population-based longitudinal cohort study of lupus in the San Francisco Bay Area. Additionally, Professor Maria Dall'Era is the PI for clinical trials investigating systemic lupus erythematosus (SLE) and lupus nephritis. She is also a member of the core team developing the American College of Rheumatology (ACR) Guidelines for the Treatment of SLE and lupus nephritis.

Professor Dall'Era received her undergraduate degree in Immunology from the University of California, Berkeley, and completed her Medical Degree from UCSF, where she later completed her Internship, Residency, and Chief Residency in Internal Medicine. She completed her Fellowship in Rheumatology at UCSF. In 2006, she received the Ephraim Engleman Award for Excellence in Arthritis Research. In 2018, she received the Edmund L. Dubois Memorial Lectureship Award from the ACR. In 2023, she received the Evelyn V. Hess award from the Lupus Foundation of America.

Professor Dall'Era has authored numerous publications and book chapters in the areas of SLE and lupus nephritis. She is a co-author of the Treatment of Lupus Nephritis chapters in Up-To-Date.

Financial Disclosures

Consultant/Advisor:

AstraZeneca; Aurinia; Biogen; GSK; Roche/Genentech.

All of the relevant financial relationships listed for this individual have been mitigated.



Professor Andrea Doria, MD
University of Padova, Padova, Italy

Andrea Doria is Professor of Rheumatology and Head of the Rheumatology Unit, Department of Medicine, Padova University School of Medicine, Italy. He is Director of the Postgraduate School of Rheumatology, University of Padua and President of Italian Society of Rheumatology.

The Unit which he leads is a tertiary referral rheumatological center of prominence within Italy, for the diagnosis and management of patients affected with systemic connective diseases. During his tenure, the Rheumatology Unit of Padua received the designation of 'EULAR Center of Excellence in Rheumatology 2022–2027'.

During his academic career Professor Doria has trained over 70 students in rheumatology and inspired some of them to be dedicated scientists.

In 2016, Professor Doria founded the European Lupus Society (SLEuro) and served as the first President of its Executive Committee; he is currently serving as the Treasurer of the same society. He is a member of the Lupus Academy Steering Committee, a member of the Systemic Lupus Erythematosus International Collaborating Clinics (SLICC) group, and a member of the OMERACT SLE Working Group.

Professor Doria was involved as "expert" in the EULAR Standing Committee for the development of clinical and therapeutic recommendations. He has also authored over 600 ISI publications (Scopus H-index 94) on SLE and other connective tissue diseases, and participates on the editorial boards of several international rheumatology and immunology journals.

Financial Disclosures

Consultant/Advisor:

AstraZeneca; Biogen; Bristol Myers Squibb; GSK; Otsuka.

Speaker:

AstraZeneca; GSK; Otsuka.

All of the relevant financial relationships listed for this individual have been mitigated.



Professor Dr Thomas Dörner, MD
Charité University Hospitals Berlin, Germany

Thomas Dörner is a board-certified Rheumatologist and Professor of Rheumatology and Hemostaseology at Charité University Hospitals, Berlin, Germany, and group leader at the German Research Center of Rheumatology, Berlin (DRFZ). He qualified in medicine in 1990 at Charité University Hospitals, Berlin, and received his board certification in internal medicine in 1995 before undertaking a postdoctoral fellowship at the University of Texas, Southwestern Medical Center in Dallas, USA, where he researched delineating molecular aspects of B-cell receptor gene usage in autoimmune diseases.

Professor Dörner has received several international and national awards, including the Senior Scholar Award of the American College of Rheumatology, the H. Schultze Award of the German League Against Rheumatism, the Randy Fischer Prize for Excellence in flow cytometry, the Schoen Award of the German Society of Rheumatology and the European Alliance of Associations for Rheumatology (EULAR) Honorary award (2023).

Professor Dörner has served as a member of Editorial Boards of leading journals in rheumatology and immunology, including Arthritis & Rheumatism, Arthritis Research & Therapy, Annals of the Rheumatic Diseases, Current Reviews in Rheumatology, the Brazilian Journal of Rheumatology, European Journal of Immunology, Lupus Science & Medicine, and Rheumatology Reviews.

Professor Dörner has led various clinical trials on rheumatic diseases, including systemic lupus erythematosus, Sjogren's syndrome, rheumatoid arthritis, and seronegative spondyloarthropathies. His research interests focus on the characterisation of disturbances of humoral autoimmunity and abnormalities of B cell subsets in the blood versus tissue (lupus, neonatal lupus syndromes, Sjogren's syndrome), exploring innovative therapeutic approaches with particular focus on B-cell directed therapy as well as improving diagnostic tools in autoimmune diseases. In this regard, he has been involved in various proof-of concept trials translating insights into mechanistic insights.

Financial Disclosures

Consultant/Advisor:

Amgen; Bristol Myers Squibb; Lilly; Novartis; Johnson & Johnson; Roche/Genentech.

Research Grants:

Bristol Myers Squibb; Novartis; Roche/Genentech.

All of the relevant financial relationships listed for this individual have been mitigated.



Assistant Professor Antonis Fanouriakis, MD
National and Kapodistrian University of Athens, Greece

Antonis Fanouriakis is an Assistant Professor of Internal Medicine-Rheumatology in the National & Kapodistrian University of Athens (Rheumatology & Clinical Immunology Unit, 4th Department of Internal Medicine, "Attikon" University Hospital, Athens, Greece). His research interests focus on the pathogenesis and treatment of systemic lupus erythematosus, with a particular interest in neuropsychiatric disease. He has participated as fellow in charge of the literature review in the EULAR Task Force to develop recommendations on the management of systemic lupus erythematosus, including the 2019 and 2023 updates.

Financial Disclosures

Consultant/Advisor:

AstraZeneca; GSK.

Speaker:

AbbVie; AstraZeneca; GSK; Lilly; UCB.

All of the relevant financial relationships listed for this individual have been mitigated.

Biographies



Dr Andrea Fava, MD

Johns Hopkins School of Medicine, Baltimore, Maryland, USA

Professor Andrea Fava is a distinguished physician-scientist and Assistant Professor of Medicine in the Division of Rheumatology at Johns Hopkins University School of Medicine. He earned his medical degree from San Raffaele Medical School in Milan, Italy, graduating Summa Cum Laude. His early passion for science and autoimmune diseases led him to conduct research at the National Institutes of Health (NIH) with Dr Anthony Fauci's group, focusing on the role of viral infections in autoimmunity.

Following his medical training, Dr Fava pursued a post-doctoral research fellowship in Molecular Rheumatology at Johns Hopkins, where he pioneered work on identifying autoreactive immune cells in scleroderma, leading to a breakthrough publication in the journal Science. He completed his Internal Medicine residency at Johns Hopkins, earning recognition with the Alpha Omega Alpha medical honor society and the Patrick Murphy Award for teaching excellence. Further specialisation included a clinical and research fellowship in Rheumatology at Johns Hopkins and a dedicated Lupus Fellowship under the mentorship of Dr Michelle Petri. He also engaged in a visiting fellowship in computational biology at Harvard/Broad Institute with Dr Soumya Raychaudhury.

Dr Fava's primary research interest lies in lupus nephritis, a severe manifestation of systemic lupus erythematosus (SLE). As an Accelerating Medicines Partnership (AMP) investigator, an NIH-led initiative, he is at the forefront of discovering novel treatable mechanisms and non-invasive biomarkers for lupus nephritis. His innovative multiomic approaches, including single-cell transcriptomics and urine proteomics, aim to develop "liquid biopsies" that could revolutionise diagnosis and treatment monitoring, potentially replacing invasive kidney biopsies. His work has identified key biological differences in lupus nephritis mechanisms, particularly in African American patients who often experience more severe disease. His findings have been presented at major scientific conferences, earning awards such as the Lupus 2019 Scientific Merit Award.

A dedicated faculty member of the Hopkins Lupus Center, Dr Fava balances his time between providing exceptional patient care to those with SLE and lupus nephritis and dedicating the majority of his efforts to groundbreaking lupus research. His influential work is regularly published in leading scientific journals, including Science, Nature Immunology, and JCI Insight, contributing significantly to the understanding and treatment of autoimmune diseases.

Financial Disclosures

Consultant/Advisor:

Annexon Biosciences; Artiva Biotherapeutics; AstraZeneca; Bain Capital; Bristol Myers Squibb; Novartis; UCB.

Research Grant:

Exagen Inc.

All of the relevant financial relationships listed for this individual have been mitigated.



Professor Richard Furie, MD

Zucker School of Medicine at Hofstra/Northwell, New York, USA

Richard Furie is a rheumatologist and Chief of the Division of Rheumatology at Northwell Health. Professor Furie's work encompasses exceptional patient care, dedicated physician education, and pivotal clinical research in anti-rheumatic drug development. As Director of Northwell's Program in Novel Therapeutics, a clinical research program in musculoskeletal disease, and the internationally recognised Systemic Lupus Erythematosus (SLE) and Autoimmune Disease Treatment Center, Professor Furie has been instrumental in advancing new therapies for SLE.

Professor Furie is regarded as one of the senior rheumatologists in the New York metropolitan area and has served as a volunteer for organisations such as the Arthritis Foundation, the Lupus Foundation of America, the Lupus Research Alliance, and Lupus Therapeutics. For over 20 years he worked on many committees of the American College of Rheumatology and was named a Master of the College in 2018. Although often featured as a speaker at national and international conferences, Professor Furie's favourite educational venue is at home with his colleagues and trainees.

Financial Disclosures

Consultant/Advisor:

Amgen; AstraZeneca; Biogen; Novartis; Roche/Genentech..

Clinical Trial Investigator:

Amgen; AstraZeneca; Biogen; Novartis; Roche/Genentech..

All of the relevant financial relationships listed for this individual have been mitigated.



Professor Iain Giles, PhD University College London, UK

Iain Giles is a Professor of Rheumatology and an Honorary Consultant Rheumatologist at University College London (UCL) and University College London Hospitals (UCLH). After qualifying from the Royal London Hospital, he completed his general medical and rheumatology clinical training at various London hospitals. He then undertook a Versus Arthritis (formerly Arthritis Research UK) funded clinical research PhD and a Clinical Scientist Fellowship at UCL. His clinical and research interests are focused on the diagnosis and long-term management of autoimmune rheumatic diseases, with a particular emphasis on Lupus and the Antiphospholipid Syndrome (APS). He also specialises in the management of these and other inflammatory rheumatic conditions during pregnancy.

Financial Disclosures


Consultant/Advisor:

UCB.

Speaker:

UCB.

All of the relevant financial relationships listed for this individual have been mitigated.



Professor David Isenberg, MD, FRCP, FAMS University College London, UK

David Isenberg is Emeritus Professor of Rheumatology at University College London (UCL). He graduated from St. Bartholomew's Hospital, London in 1973, and trained in general medicine, rheumatology, neurology, psychiatry and gastroenterology, becoming a Research Fellow at UCL/The Middlesex Hospital in 1979. He was awarded his MD in 1984, based on his studies of myositis. During a year of research at Tufts University, Boston, he became interested in autoantibody structure/function and origin. He was appointed Consultant Rheumatologist in 1984, Professor in 1991 and became the ARC Diamond Jubilee Chair of Rheumatology at UCL in 1996. He has fellowships of both the Royal College of Physicians and the Academy of Medical Sciences.

Financial Disclosures

Consultant/Advisor:

Amgen; AstraZeneca; Biogen; GSK; Lilly; Merck Serono; Pfizer; Servier; UCB.

All of the relevant financial relationships listed for this individual have been mitigated.

Professor Isenberg is on the Editorial Boards of five journals, including The Journal of Rheumatology. He is past-Chair of the British Isles Lupus Assessment Group, current Chair of the Lupus UK's Research Committee and past-Chair of the Systemic Lupus International Collaborating Clinics group (1998–2003). During the past 20 years, Professor Isenberg has undertaken many roles at the Versus Arthritis charity and was on the Executive Board from 2013 to 2021.

Professor Isenberg is past-President of the British Society for Rheumatology (2004–2006), chaired the Society's Biologics Register Committee for 5 years (2006–2011) and is a co-Founder of The Lupus Academy. Professor Isenberg was the 2010 recipient of the Evelyn V. Hess Prize from the Lupus Foundation of America for his contribution to lupus research and treatment. He has authored over 600 original articles, 300 reviews/chapters and 20 books, many on topics related to lupus.

Professor Isenberg's principal clinical interests are the development of disease activity and damage assessment tools in patients with lupus. His specialist interest is in the autoantibodies associated with systemic lupus erythematosus, Sjogren's syndrome, myositis and antiphospholipid antibody syndrome. In 2016 he became a Master of the American College of Rheumatology and in 2017 received the Rheumeritus award from the Portuguese Society for Rheumatology. His alter ego writes and plays for Lupus Dave and The Davettes, probably rheumatology's top rock group.

Biographies



Professor Dr Gerhard Krönke, MD

German Rheumatology Research Center, Berlin, Germany

After graduating from the Medical University of Vienna in 2002, Gerhard Krönke worked as postdoctoral researcher at the Medical University of Vienna (2002–2004) and the University of Virginia, Charlottesville (2004–2006). From 2006–2015 he conducted his clinical training in Internal Medicine and subsequently in Rheumatology at the University Hospital Erlangen, where he worked as Senior Physician at the Department of Internal Medicine 3 from 2012–2023. In 2016, he was appointed Professor of Translational Immunology at the University of Erlangen-Nürnberg. In 2023 he moved to Berlin where he is now serving as Chair and Director of the Medical Department of Rheumatology and Clinical immunology at the Charité University Hospital, Berlin. He received an ERC Starting Grant as well as an ERC Consolidator Grant and is currently acting as the spokesperson of the DFG research unit FOR2886 “PANDORA” (Pathways triggering Autoimmunity and Defining Onset of early Rheumatoid Arthritis). His research focuses on cellular, molecular and metabolic pathways involved in the maintenance and break of immunological self-tolerance as well as the onset and resolution of inflammatory disease.

Gerhard Krönke’s research work focuses on the molecular mechanisms contributing to the development of immune mediated inflammatory diseases (IMiDs) such as rheumatoid arthritis and systemic lupus erythematosus. Recent work of his lab helped to identify the molecular mode of action of glucocorticoids. A particular focus of his research lies on the identification of novel therapeutic targets and treatment approaches, which resulted in the introduction of novel therapeutic strategies such as CAR T cells and T cell engagers as newly emerging therapeutic principles for IMiDs.

Financial Disclosures

Consultant/Advisor:

GSK; Johnson & Johnson; Lilly; Takeda.

Speaker:

Bristol Myers Squibb; GSK, J&J; Lilly.

All of the relevant financial relationships listed for this individual have been mitigated.



Professor Annegret Kuhn, MD, MBA, CHCIO

University of Münster and University of Passau, Germany and Amsterdam Medical Center, The Netherlands

Annegret Kuhn is Professor (adj.) of Dermatology and Venereology at the University of Münster as well as Research Affiliate and University Lecturer at the School of Business, Economics, and Information Systems at the University of Passau, Germany. She is also Visiting Professor at the Department of Clinical Immunology and Rheumatology at the Amsterdam Medical Center, the Netherlands.

Professor Kuhn obtained her qualifications in Dermatology and Venereology at the University of Duesseldorf, Germany, where she also received her Doctorate in Medicine and her qualification as a University Lecturer. From 2005 to 2009 she was a Heisenberg-Fellow of the German Research Foundation (DFG) and worked in University departments and scientific institutions such as the Max Planck Institute for Molecular Biomedicine in Münster and the German Cancer Research Center in Heidelberg, Germany.

Professor Kuhn’s main clinical and scientific interest is translational immunology, with a particular interest in the pathogenesis, diagnosis and treatment of cutaneous manifestations in lupus erythematosus. In addition, she has extensive knowledge in all areas of Dermatology and Venereology and has many years of experience in the academic care of inpatients and outpatients with autoimmune diseases. Professor Kuhn chairs national and international guideline committees and works on new diagnostic and therapeutic strategies for cutaneous lupus erythematosus. From 2004 to 2017 she was Chair of the European Society of Cutaneous Lupus Erythematosus (EUSCLE) and is a member of several German and international medical societies and reviewer for several clinical and scientific journals. Professor Kuhn has published widely in high impact journals, including more than 150 original and review articles.

Financial Disclosures

Consultant/Advisor:

Bristol Myers Squibb; Merck Serono.

All of the relevant financial relationships listed for this individual have been mitigated.



Professor Dr Eicke Latz, MD, PhD
German Rheumatology Research Center, Berlin, Germany

Eicke Latz is a physician-scientist and internationally recognized leader in innate immunity and inflammation research. Since 2023, he has served as Scientific Director of the German Center for Rheumatology Research (DRFZ), a Leibniz Institute in Berlin, and as Professor of Experimental Rheumatology at the Charité – Universitätsmedizin Berlin.

After receiving his medical degree from the Universities of Göttingen and Berlin, Professor Latz trained in intensive care medicine at Charité. In 2001, he moved to the United States for postdoctoral research at Boston University and later became a professor at UMass Chan Medical School. In 2010, he returned to Germany to establish the Institute for Innate Immunity at the University Hospital Bonn, which he led for over a decade. During this time, he also co-directed the Cluster of Excellence “ImmunoSensation².”

Professor Latz’s research explores how the innate immune system maintains health and contributes to chronic inflammatory diseases such as rheumatoid arthritis, atherosclerosis, and Alzheimer’s disease. A major focus is on the molecular mechanisms that control immune activation and inflammatory signaling.

Professor Latz has authored more than 300 peer-reviewed publications and has been recognized as a Highly Cited Researcher in Immunology every year since 2014. He was elected to the German National Academy of Sciences Leopoldina in 2016 and received the prestigious Gottfried Wilhelm Leibniz Prize in 2018.

In addition to his academic career, Professor Latz is a serial biotech entrepreneur. He has co-founded several companies, including IFM Therapeutics (2017), Dioscure Therapeutics (2020), the Stealth Biotech Beren Therapeutics (2020), Odyssey Therapeutics (2022) and Metalmune Therapeutics (2023), to translate fundamental discoveries into new therapeutic and preventive approaches.

Financial Disclosures

Consultant/Advisor/Stock Owner:

Beren Therapeutics; Dioscure Therapeutics; IFM Therapeutics; Metalmune Therapeutics; Odyssey Therapeutics; Stealth Biotech.

All of the relevant financial relationships listed for this individual have been mitigated.



Professor Sandra Navarra, MD
University of Santo Tomas, Manila, Philippines

Sandra Navarra is Professor and Head of Rheumatology at University of Santo Tomas Manila, Philippines. She is a member of the Lupus Academy Steering Committee, and a founding and executive board member of both the Asia Pacific Lupus Collaboration (APLC) and the Asian Lupus Nephritis Network (ALNN). Professor Navarra is Director of the Lupus Inspired Advocacy (LUISA) Project for lupus education and research, and the People Empowerment for Arthritis and Lupus (PEARL) movement for lay education and medical assistance programmes, both administered by Rheumatology Educational Trust Foundation Inc. (RETFI) in the Philippines. She has served as Secretary General of Asia Pacific League of Associations for Rheumatology (APLAR) and is a former President of Philippine Rheumatology Association (PRA). She currently heads the PRA Special Interest Group (SIG) on systemic lupus erythematosus (SLE) and is eminent member of the APLAR SLE-SIG.

Professor Navarra has published widely in the field of lupus and other rheumatic diseases and is the recipient of several university, national and regional awards for her contributions to education and research, including the Philippine College of Physicians Most Distinguished Physician award and the APLAR Master award. She has organised several national and regional educational meetings including the Ten Topics in Rheumatology – Asia (November 2009), first Asian Lupus Summit (November 2012), Asian Lupus Summit by Lupus Academy (March 2014), Lupus Academy (Philippine) Roadshow Meetings (May 2016, November 2017, May 2018, February 2023), Lupus for the Internist (May 2019) and Lupus webinar series (October-December 2020).

Financial Disclosures

Consultant/Advisor:

AstraZeneca; Viatris (Idorsia).

Data Monitoring Committee:

Biogen.

Speaker:

Otsuka.

All of the relevant financial relationships listed for this individual have been mitigated.



Professor Mike T. Nurmohamed, MD, PhD **Amsterdam UMC and Reade, Amsterdam, The Netherlands**


Mike Nurmohamed is Professor of Rheumatology at Amsterdam UMC (Vrije Universiteit Amsterdam) and Head of the Rheumatology Research Department at Reade, Amsterdam. He received his medical degree from the University of Amsterdam and obtained a PhD in 1994 on the prevention of venous thrombosis. After specialisation in internal medicine, epidemiology, and rheumatology, he developed a career that combines clinical care, academic research, and education.

Professor Nurmohamed is internationally recognised for his pioneering work on cardiovascular disease (CVD) in inflammatory rheumatic diseases. He was one of the first to demonstrate the markedly increased risk of CVD in rheumatoid arthritis and related conditions. His research has shaped clinical practice, particularly in the area of cardiovascular risk assessment and prevention. He has chaired several EULAR task forces, most recently the 2022 update of recommendations on CVD risk management in rheumatic diseases.

With over 450 publications and more than 18,000 citations, he is a frequent speaker at major rheumatology congresses and serves on the editorial boards of *Annals of the Rheumatic Diseases* and *The Journal of Rheumatology*. He also serves on the Dutch Medicines Evaluation Board and remains actively involved in mentoring future leaders in rheumatology.

Financial Disclosures

None.



Professor Bernardo Pons-Estel, MD **Regional Center for Autoimmune and Rheumatic Diseases and the Cardiovascular Institute of Rosario, Argentina**

Bernardo Pons-Estel is Head of the Regional Center for Autoimmune and Rheumatic Diseases (CREAR) and the Cardiovascular Institute of Rosario, Argentina. He received his medical degree from the National University of Rosario. Later he received a Rheumatology Scholarship and went to complete a fellowship at the Division of Rheumatology at the Bellevue Hospital, New York University Medical Center (NYUMC). He completed his training in rheumatology at the University of Missouri, Columbia, and as Assistant Research Professor at the Department of Medicine, Irvington House Institute, NYUMC, USA.

Professor Pons-Estel is the main coordinator for the Latin American Group for the Study of Systemic Lupus Erythematosus (GLADEL), and is co-leader of the Latin American Group for the Study of Rheumatic Diseases in Indigenous People (GLADERPO). He was speaker at more than 300 national and international conferences, and he has more than 180 publications in international indexed journals.

Professor Pons-Estel is the Chair of the Lupus Study Group of Pan American League of Associations of Rheumatology (PANLAR) and member of the Steering Committees of the Lupus Academy, Systemic Lupus International Collaborating Clinics (SLICC), and Definition Of Remission In SLE (DORIS) group.

Professor Pons-Estel was distinguished with the Pan American Spirit award; Master of PANLAR, Master of the American College of Rheumatology, Master of the Argentine Society of Rheumatology, and more recently as Gold Medal Anibal Ruiz Moreno from PANLAR.

Financial Disclosures

Speaker:

AstraZeneca; GSK; Janssen;
Novartis.

All of the relevant financial relationships listed for this individual have been mitigated.



Professor Dr Georg Schett, MD
Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany

Georg Schett is Professor of Internal Medicine and since 2006 head of the Department of Medicine 3 - Rheumatology and Immunology at Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg in Germany.

Professor Schett graduated from the University of Innsbruck (Austria) in 1994. After completing his dissertation at medical school, he worked as scientist at the Institute of BioMedical Aging Research of the Austrian Academy of Science in Innsbruck. Two years later, he joined the Department of Medicine at the University of Vienna, where he completed his postgraduate training in Internal Medicine and subsequently in Rheumatology. In 2003 he was promoted to Professor of Internal Medicine. Before accepting his position as the Chair of the Department of Internal Medicine 3 in Erlangen, he worked as a scientist in the United States of America for one year.

Georg Schett's scientific work includes a broad spectrum of clinical and immunological issues, particularly the molecular basics of immune-inflammatory diseases. Initially, he investigated the immunology of atherosclerosis and focused on antibody-mediated endothelial cell damage. His research work led to the understanding of the phenomenon of lupus erythematosus (LE)-cells in 2007. He was awarded the renowned START Award in 2002 and established a research group for arthritis in Vienna. In 2008, he initiated in collaboration with colleagues the priority program IMMUNOBONE in Germany, funded by the German Research Foundation (DFG). IMMUNOBONE aims to elucidate the interactions between the skeletal and the immune systems. Since 2015, Professor Schett has led the DFG collaborative research centre 1181 "Checkpoints for Resolution of Inflammation" in Erlangen. Additionally, he is spokesperson of the project METARTHROS, funded by the Federal Ministry of Education and Research, which investigates the impact of the metabolism on arthritis. In 2019, he received funding for the ERC-Synergy grant "4D+ nanoSCOPE Advancing osteoporosis medicine by observing bone microstructure and remodelling using a four-dimensional nanoscope" of which he is spokesperson. 4D+ nanoSCOPE aims to develop tools and techniques to permit time-resolved imaging and characterisation of bone in three spatial dimensions (both in vitro and in vivo), thereby permitting monitoring of bone remodelling and revolutionising the understanding of bone morphology and its function.

In 2021, Professor Schett was appointed Vice President for Research at the Friedrich-Alexander-Universität Erlangen-Nürnberg and became a Leopoldina member of the German National Academy of Sciences.

Professor Schett's scientific work has been honored with several awards, including the Carol-Nachman Prize from Wiesbaden. In March 2023, Professor Schett received the 2023 "Funding Prize in the Gottfried Wilhelm Leibniz Programme" awarded by the DFG. He has published over 1050 peer-reviewed papers.

Financial Disclosures

Consultant/Advisor:

UCB.

Speaker:

Bristol Myers Squibb; Janssen; Kyverna; Novartis.

All of the relevant financial relationships listed for this individual have been mitigated.

Biographies



Dr Eva Schrezenmeier, MD, PhD
Charité University Hospitals Berlin, Germany

Eva Schrezenmeier is an Attending Physician at the Department of Nephrology and Intensive Care Medicine at Charité University Hospitals Berlin.

Dr Schrezenmeier completed her medical education at Charité University Hospitals Berlin, with clinical clerkships at Cleveland Clinic, Sheba Medical Center, and McGill University. She earned her Doctorate for her research on (pro)renin receptor signal transduction.

Dr Schrezenmeier's postdoctoral research is conducted in Nephrology and the German Rheumatism Research Center Berlin. Her research interests focus on B cell immunology, particularly the roles of protective and pathological B and plasma cells in autoreactivity as well as alloreactivity.

Financial Disclosures

Consultant/Advisor:

Otsuka.

Research Grants:

HiBio.

Speaker:

AstraZeneca.

Travel Grants:

Chiesi.

All of the relevant financial relationships listed for this individual have been mitigated.



Professor Gregg Silverman, MD
New York University Grossman School of Medicine, New York, USA

Gregg Silverman is Professor of Medicine and Pathology with Tenure, Associate Chief of the Division of Rheumatology, and the Mamdouha S. Bobst Endowed Professorship of Internal Medicine at New York University (NYU) Grossman School of Medicine, New York, USA.

Professor Silverman received his baccalaureate degree from Brandeis University, then MD from Rutgers Medical School, studying during the summers under Dr Anthony Fauci at the National Institutes of Health (NIH). He completed his Internal Medicine residency at University of California (UC) San Diego and his rheumatology fellowship at Scripps Clinic. Formerly, a member of the faculty of UC San Diego for over 20 years, over 13 years ago he moved his research efforts and clinical practice to NYU.

Professor Silverman has been NIH-supported for over 30 years and recipient of many grants and awards. He has authored more than 200 publications and is an elected member of the American Society for Clinical Investigation, the Henry Kunkel Honor Society. In 2021, he was also elected as a Master of the American College of Rheumatology, which signifies the highest level of accomplishment in this clinical subspecialty.

Professor Silverman is a clinical rheumatologist, practicing at Bellevue Hospital with a special interest in understanding the pathogenesis in rheumatic autoimmune diseases and the role of the microbiome.

Financial Disclosures

Consultant/Advisor:

GSK.

Clinical Trial Investigator:

Roche/Genentech; Sanofi.

All of the relevant financial relationships listed for this individual have been mitigated.



Professor Dr Thomas Skripuletz, MD

Department of Neurology Hannover Medical School, Hannover, Germany

Thomas Skripuletz is currently the Head of the Cerebrospinal Fluid Laboratory and a Professor of Neuroimmunology at Hannover Medical School in Germany. Prior to this, he completed his habilitation (postdoctoral qualification) and served as a Senior Physician and Group Leader at the same institution.

Professor Skripuletz's career has focused on the intersection of neurology and immunology. His research interests are primarily in neuroimmunology, with a strong focus on multiple sclerosis. Specifically, he investigates myelin repair mechanisms, the role of various cells like astrocytes and microglia in this process, and the identification of biomarkers in cerebrospinal fluid, such as kappa free light chains. He also conducts research on Sjögren's disease and other neuroinflammatory conditions, including chronic inflammatory demyelinating polyneuropathy, and explores the neurological effects of immuno-oncology treatments and infectious diseases like progressive multifocal leukoencephalopathy.

Financial Disclosures

Consultant/Advisor:

Alexion; Alnylam; Argenx;
Biogen; Centogene; CSL
Behring; Grifols; Hexal AG;
Janssen; Merck; Novartis;
Roche; Sanofi; SOBI; Viartis.

Research Grants:

Alnylam; CSL Behring; Merck;
Novartis; Siemens.

Speaker:

Alexion; Alnylam; Argenx;
Bayer; Biogen; Bristol Myers
Squibb; Celgene; Centogene;
CSL Behring; Euroimmun;
Grifols; Hexal AG; Horizon;
Janssen; Merck; Novartis;
Pfizer; Roche; Sanofi; Siemens;
SOBI; Teva; Viartis.

All of the relevant financial relationships listed for this individual have been mitigated.



Dr Ana-Luisa Stefanski, MD, PhD

Charité University Hospitals Berlin, Germany

Ana-Luisa Stefanski is a rheumatologist and clinician scientist at Charité University Hospital Berlin.

Following her PhD from the University of Witten-Herdecke in 2011, Dr Stefanski was awarded multiple research scholarships, including those from the Bangerter-Rhyner Foundation (2017), the German Society of Rheumatology (2020), and Charité – Universitätsmedizin, Berlin (2023). She is the recipient of the poster award at the last Lupus Academy in 2024 in Amsterdam. Her commitment to medical education is reflected in her role as a co-author of the EULAR School of Rheumatology's course on Systemic Lupus Erythematosus.

Dr Stefanski's research focuses on B lineage cells, with particular emphasis on their translational relevance in rheumatic diseases and pregnancy. Since 2022, she has been part of the joint rheumatology and obstetric clinic at Charité, Berlin.

Financial Disclosures

None.

Biographies



Professor Y.K. Onno Teng, MD, PhD
Leiden University Medical Center, The Netherlands

Professor Onno Teng is a Nephrology clinician-scientist at the department of Internal Medicine of the Leiden University Medical Center (LUMC) where he leads the national and european recognised centre of expertise for lupus, Vasculitis and Complement-mediated systemic diseases (LuVaCs). He is Professor of Nephrology in renal autoimmune diseases at the University of Leiden and Chair of the national foundation of Autoimmune Research & Collaboration Hubs (ARCH).

Professor Teng has founded a clinical research programme for the development of novel treatment strategies in patients with renal autoimmune diseases including lupus nephritis and ANCA-associated vasculitis. He also conducts a translational research programme focused on neutrophil extracellular traps, B cell and plasma cell immunology collectively aimed at innovative immune monitoring of novel treatment strategies for LuVaCs patients.

Professor Teng is actively involved as clinical teacher for Nephrology, Immunology and Basic Physiology & Anatomy in the curriculum of Medicine at Leiden University. He supervises medical students for their scientific as well as clinical internships and clinical bedside teaching of the LUMC Internal Medicine Residents.

Financial Disclosures

Consultant/Advisor:

AstraZeneca; Alexion; CSL Vifor; GSK; Novartis; Otsuka Pharmaceuticals.

Clinical Trial Investigator:

CSL Vifor; GSK; Novartis.

All of the relevant financial relationships listed for this individual have been mitigated.



Professor Angela Tincani, MD
Rheumatology and Clinical Immunology Unit-ERN ReCONNET Center- ASST Spedali Civili di Brescia, Dpt. Clinical and Experimental Science-University of Brescia, Italy.

Professor Angela Tincani is Senior Consultant at Rheumatology and Clinical Immunology Unit at the “ASST-Spedali Civili di Brescia”, Italy and Professor of Rheumatology at the University of Brescia, Italy. She was previously Head of the Rheumatology and Clinical Immunology Unit at the “ASST-Spedali Civili di Brescia”, Italy.

Professor Tincani has been Committee Member or Chair of many international conferences on systemic lupus erythematosus, antiphospholipid antibodies, autoimmunity, and pregnancy in rheumatic diseases. She was involved in the EULAR task forces as an “expert” for the development of recommendations.

She has authored more than 300 publications on the management of patients with systemic autoimmune diseases. Several articles focus on reproductive related issues such as: 1) management of patients with rheumatic diseases during pregnancy; 2) use of anti-rheumatic drugs during pregnancy and lactation; 3) evaluation of different autoimmune diseases and autoantibodies as risk factors for poor gestational outcomes.


Professor Tincani has a recognised experience in the clinical management of patients with autoimmune rheumatic diseases. In addition, she is responsible of the multidisciplinary Pregnancy Clinic in Rheumatic Diseases since 1990.

Financial Disclosures

Consultant/Advisor:

Galapagos; UCB.

All of the relevant financial relationships listed for this individual have been mitigated.



Professor Murray Urowitz, MD University of Toronto, Canada

Murray Urowitz is a Professor Emeritus with the Temerty Faculty of Medicine, University of Toronto. He was the Director of the Centre for Prognosis Studies in the Rheumatic Diseases Toronto Western Hospital from 1995 to 2022 and Director of the Toronto Lupus Program from 1970 to 2022.

Professor Urowitz established the University of Toronto Lupus Clinic and Lupus Databank Research Program in 1970. This extensive longitudinal database is one of the largest such databanks in the world with over 2150 patients and has allowed for numerous findings which have changed the way lupus is diagnosed and managed. He was Senior Scientist with the Krembil Research Institute and Schroeder Arthritis Institute.

Professor Urowitz was a founding member of the Ontario Lupus Association (now Lupus Ontario) and was president of the Lupus Council of the American Rheumatology Association. He was also a founding member of the Systemic Lupus International Collaborating Clinics (SLICC) group and Director of the SLICC Registry for Atherosclerosis. In 1995 he received the Distinguished Rheumatologist Award of the Canadian Rheumatology Association and in 2009 he received the Evelyn V. HESS Award for outstanding contributions to lupus research, awarded by the Lupus Foundation of America. He also received the Queen Elizabeth Diamond Jubilee Medal for longstanding contributions to lupus research work in the field of rheumatology in 2015, and was awarded a Lifetime Achievement Award for commitment to the field of lupus by Lupus Ontario in March 2016. In 2017 he was awarded the Distinguished Clinical Investigator Award for exceptional contributions to the field of rheumatology by the American College of Rheumatology. In May of 2019 he received the University of Toronto Dean's Alumni Lifetime Achievement Award for Global Impact and in 2020 he received the CRA Masters Award for achievements in rheumatology from the Canadian Rheumatology Association. In 2023 he was awarded the University Health Network Global Impact Award.

Professor Urowitz has published over 469 peer-reviewed papers and 46 book chapters and has supervised the training of over 130 fellows in rheumatology especially in systemic lupus erythematosus.

Professor Urowitz's research has been by supported grants from the Canadian Institutes of Health Research, National Institutes of Health, the Arthritis Society of Canada, Heart and Stroke Foundation of Canada, Lupus Ontario, Lupus Canada and investigator-initiated study pharmaceutical support and donations from the Lou and Marissa Rocca and Mark and Diana Bozzo Families.

Financial Disclosures

Consultant/Advisor:

GSK; MSD.

Speaker:

AstraZeneca; GSK.

All of the relevant financial relationships listed for this individual have been mitigated.

Biographies



Financial Disclosures

Consultant/Advisor:

AbbVie; AstraZeneca;
Biogen; Bristol Myers Squibb;
Galapagos; GSK; Janssen;
Pfizer; RemeGen; UCB.

Research Grants:

Alfasigma; AstraZeneca; Bristol
Myers Squibb; Galapagos;
MSD; Novartis; Pfizer; Roche;
Sanofi; UCB.

Speaker:

AbbVie, AstraZeneca;
Biogen; Bristol Myers Squibb;
Galapagos; GSK; Janssen;
Pfizer; RemeGen; UCB.

*All of the relevant financial
relationships listed for this
individual have been mitigated.*

Professor Ronald van Vollenhoven, MD, PhD

Amsterdam University Medical Center, and Amsterdam Rheumatology and Immunology Center, The Netherlands

Ronald van Vollenhoven is a rheumatologist at the Department of Rheumatology and Clinical Immunology, Amsterdam UMC and Director of the Amsterdam Rheumatology Center in Amsterdam, the Netherlands.

Professor van Vollenhoven received his MD and PhD degrees from the University of Leiden in The Netherlands. After graduating in 1984 he pursued immunology research at Cornell Medical College in New York, followed by specialty training at the State University of New York at Stony Brook and at Stanford University, leading to American Board of Internal Medicine certification in Internal Medicine and Rheumatology. From 1993 to 1998 he held a faculty appointment as Assistant Professor of Medicine in the Division of Immunology and Rheumatology at Stanford University, and from 1995 he was the Medical Services Chief and Fellowship Director in that division. From 1998 until 2015 Professor van Vollenhoven worked in Stockholm, Sweden as Professor and Chief of the Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID) at the Karolinska Institute and Senior Physician and Chief of the Clinical Trials Unit in the Department of Rheumatology at the Karolinska University Hospital.

In January 2016 Ronald van Vollenhoven was appointed as Professor of Rheumatology at the University of Amsterdam and the VU University, and Chair of the Department of Rheumatology and Clinical Immunology of Amsterdam UMC. He is also the Director of the Amsterdam Rheumatology Center in Amsterdam, The Netherlands. In September 2024 he stepped down as Department Chair but continued his role in the Department as clinician-educator and research leader.

Professor van Vollenhoven's research interests focus around the development and systematic evaluation of biological and immunomodulatory treatments for the rheumatic diseases. With his co-workers, he established the Stockholm registry for biological therapies (the STURE database) which supported research projects relating to clinical efficacy, pharmacology, outcomes and pharmacoeconomics. He has been Principal Investigator in many clinical trials of novel therapies in rheumatic diseases and has contributed to a number of important investigator-initiated trials including the SWEFOT, ADMIRE, DOSERA and NORD-STAR trials. He has published over 500 original papers (H-index: 110), book chapters and reviews, and is associate-editor of Dubois' Lupus Erythematosus (Elsevier, 2014), editor of the textbook Clinical Therapy Research in the Inflammatory Diseases (World Scientific Press, 2015), author of the monograph Biological Therapy of Rheumatoid Arthritis (Springer, 2015) and co-author, with Professor Laurent Arnaud, of the Handbook of Systemic Lupus Erythematosus (Springer, 2017). He is an honorary member of EULAR and of several rheumatological societies, and in 2019 he was awarded the Dutch Rheumatology Society's highest award, the Jan van Breemen medal.

Professor van Vollenhoven is Editor-in-Chief of the on-line journal *Lupus Science & Medicine*. He is also the Chair of the EULAR Research Committee, past-chair of the Swedish Rheumatology Society Professors' Council, and (co-)initiator of the CERERRA registries collaboration, the NORD-STAR collaboration for Nordic trials in the rheumatic diseases, and the Treat-to-Target-in-SLE and DORIS initiatives. Professor van Vollenhoven is married and has two grown-up children. Outside his professional life he is an avid classical pianist.



Professor Ed Vital, MB ChB, FRCP, PhD
Leeds Teaching Hospitals NHS Trust and University of Leeds, UK

Ed Vital is an Professor of Translational Medicine and Honorary Consultant Rheumatologist, at Leeds Teaching Hospitals NHS Trust in the UK. He is the Head of the Leeds Lupus Research Group with interests in early disease, skin disease, musculoskeletal outcome measures, translational immunology, and B cell therapies.

Professor Vital studied Medicine and Surgery at the University of Manchester and became a Member of the Royal College of Physicians in 2004 and a Fellow in 2024. In 2012, he completed his PhD, at the University of Leeds studying B-cell depletion therapy.

He is General Secretary of SLEuro, Chair of the British Society for Rheumatology Special Interest Group for systemic lupus erythematosus (SLE), and Chair of the British Isles Lupus Activity Group, a member of the global steering committee of Transform Lupus and Founder and Chair of the Lupus Forum. In 2018 he won the Medical Research Foundation Emerging Leaders Award, in 2019, he won the British Society for Rheumatology Michael Mason Prize, and in 2023 a European Research Council Consolidator Fellowship.

Professor Vital's research covers a broad range of clinical translational themes. In early SLE he has shown that lupus is preceded by an "At Risk" phase, which is an immunologically complex dynamic equilibrium in which SLE is not inevitable. He has shown that development of SLE can be predicted by Type I interferon (IFN) status. From this finding, his group then showed that from the earliest phases of pre-clinical disease, Type I IFN production does not come from plasmacytoid dendritic cells as once thought, but from non-hematopoietic cells in target organs such as the skin prior to inflammation, reversing the concept of a conventional model of the relationship between haematopoietic immunity and target organ. In established disease he has extensively investigated the efficacy and mechanism of action of B-cell depletion, demonstrating the importance and mechanism of depth of depletion, and the existence of B-cell independent inflammation in cutaneous disease. In lupus arthritis he used imaging to develop new outcome measures, trial designs and treatment strategies. His current key research themes are PREVENT-SLE - characterisation of At Risk immunity and causes of progression to SLE through an ERC fellowship and FIRST – an NIHR funded clinical trial of first-line biologics. He has published more than 135 papers on SLE and related diseases.

Financial Disclosures

Consultant/Advisor:

AbbVie; AstraZeneca; Bristol Myers Squibb; Lilly; Merck; Novartis; Otsuka; Roche; Ventus Therapeutics.

All of the relevant financial relationships listed for this individual have been mitigated.



Professor Alexandre Voskuyl, MD, PhD
Amsterdam University Medical Centers, The Netherlands

Alexandre Voskuyl is a Rheumatologist and Professor of Rheumatology at the Department of Rheumatology and Clinical immunology of the Amsterdam University Medical Centers, VUmc, Amsterdam, The Netherlands.

Professor Voskuyl has a special interest in systemic autoimmune disease, in particular systemic lupus erythematosus (SLE) and systemic sclerosis (SSc). His scientific work is focused on clinical outcomes and biomarkers in systemic autoimmune diseases. He is a member of the international taskforce definition of remission in SLE (Definition Of Remission In SLE [DORIS]), and he has also been a member of Systemic Lupus International Collaborating Clinics (SLICC) group since 2016. He has participated in several national and international recommendations, including the 2019 joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendation on the management of lupus nephritis.

Professor Voskuyl has been President and/or member of several national taskforces on SLE, SSc, and small vessel vasculitis. He has authored over 300 ISI publications. He has longstanding clinical experience in the management of systemic autoimmune diseases and his centre is an international centre of excellence for systemic autoimmune diseases.

Financial Disclosures

Consultant/Advisor:

AstraZeneca; Biogen.

Research Grants:

Boehringer Ingelheim; GSK.

All of the relevant financial relationships listed for this individual have been mitigated.

Biographies



Dr Brittany Weber, MD, PhD

University of Texas Southwestern Medical Center, Dallas, Texas, USA

Brittany Weber leads the cardiorheumatology program at the University of Texas Southwestern Medical Center.

Dr Weber is a graduate of the University of Pennsylvania School of Medicine with an MD, PhD in Immunology. She received internal medicine training at the Brigham and Women's Hospital, where she also served as a Chief Medical Resident, and undertook her cardiovascular training, including an advanced cardiovascular imaging research fellowship. Dr Weber also served as Director of the Cardio-Rheumatology clinic and Assistant Professor of Medicine at Harvard Medical School, and Associate Physician in Prevention Cardiology and Cardiovascular Imaging at Brigham and Women's Hospital.

Dr Weber's clinical interests include cardiovascular risk stratification and prevention in patients with systemic inflammatory disorders. Her research leverages advanced cardiovascular imaging (stress/PET and coronary CT), biomarkers, and immunology to investigate the relationships between systemic inflammation and CVD, with a focus on the coronary microcirculation and novel metrics of atherosclerotic plaque imaging. Her multi-disciplinary clinical and research programme includes close collaborations between cardiology, rheumatology, and dermatology disciplines. As a direct extension of her work, Dr Weber also has expertise in idiopathic and autoimmune recurrent pericarditis and myocarditis. As a testament to her success in this short time frame, she is the recipient of the 2025 American College of Cardiology (ACC) Douglas P. Zipes Distinguished Young Scientist Award.

Financial Disclosures

Consultant/Advisor:

Bristol Myers Squibb;
Horizon Therapeutics; Kiniksa
Pharmaceuticals; Novo
Nordisk.

*All of the relevant financial
relationships listed for this
individual have been mitigated.*



Professor Victoria P. Werth, MD, PhD

Hospital of the University of Pennsylvania and the Veteran's Administration Medical Center, Pennsylvania, Philadelphia, USA

Financial Disclosures

Consultant/Advisor:

AbbVie; Alpine Immune Sciences; Amgen; Anaptysbio; Argenx; AstraZeneca; Cabaletta Bio; Calyx; Caribou; CSL Behring; Biogen; Bristol Myers Squibb; Crisalis; Cugene; EMD Serono; Evomune; Gilead; GSK; Horizon Pharmaceuticals; Immunovant; Innovaderm; Janssen; Kwoya Kirin; Lilly; Merck; Nektar; Nuvig Pharmaceuticals; Pfizer; Rome Pharmaceuticals; Regeneron; Sanofi; Takeda; UCB; Ventus; Viela Bio; Xencor.

Research Grants:

Amgen; AstraZeneca; Biogen; Bristol Myers Squibb; Corbus Pharmaceuticals; CSL Behring; Gilead; Horizon; Pfizer; Priovant; Regeneron; Rome Pharmaceuticals; Ventus; Viela.

All of the relevant financial relationships listed for this individual have been mitigated.

Victoria Werth is a Professor of Dermatology and Medicine at the Perelman School of Medicine at the University of Pennsylvania and Chief of the Division of Dermatology at the Philadelphia Veterans Administration Hospital. Professor Werth earned her medical degree from Johns Hopkins University School of Medicine in Baltimore, Maryland. She completed a residency in internal medicine at Northwestern Memorial Hospital in Chicago, Illinois, and dermatology residency and immunodermatology fellowship at New York University School of Medicine in New York, funded by the NIH and Dermatology Foundation. She joined the faculty at Penn in 1989 and has developed an internationally recognised program in autoimmune skin diseases.

Professor Werth is a co-founder of the Rheumatologic Dermatology Society and previous President of the group. She is co-founder of the Medical Dermatology Society, and a recipient of their lifetime achievement award. She initiated the combined internal medicine/dermatology residency program in the US, which has successfully trained prominent leaders in complex medical dermatology. She has a longstanding interest in clinical and translational research pertaining to autoimmune skin diseases, including cutaneous lupus erythematosus (CLE), dermatomyositis, and autoimmune blistering diseases, with a focus on improving the outcomes of autoimmune dermatologic diseases. She has developed and validated disease severity tools now used in many international trials for these diseases, with a goal of advancing evidence for current and new therapeutics. Her laboratory studies include studies in cutaneous lupus and dermatomyositis that relate to pathogenesis and heterogeneity of response to treatment, and ultraviolet light effects on skin. Recent clinical studies have examined mechanistic effects of therapeutics in CLE, as well as subset-specific expression of cytokine signatures. She has received numerous honours for her work, including the lifetime achievement award from the Medical Dermatology Society, the Rose Hirschler Award from the Women's Dermatologic Society, and the American Skin Association's Research Achievement Award in Autoimmune & Inflammatory Skin Disorders, and the Lifetime Career Educator Award, Dermatology Foundation. Her work has been funded by the Dermatology Foundation, National Institutes of Health, Department of Defense, the Veterans Administration, the Lupus Research Alliance, the Lupus Foundation of America, the Myositis Association, the International Pemphigus and Pemphigoid Foundation, Childhood Arthritis and Rheumatology Research Alliance, and industry.

About the Lupus Academy

Mission

The Lupus Academy is a not-for-profit, long-term initiative committed to improving patient outcomes in SLE and allied diseases. By providing a highly interactive educational forum, the Lupus Academy is dedicated to sharing best clinical practice through the dissemination and discussion of cutting edge scientific and clinical research.

Meeting Organisation

The 14th Annual Meeting of the Lupus Academy has been developed under the control of the meeting Chairs: Professor Thomas Dörner (Germany) and Professor Maria Dall'Era (USA), on behalf of the Steering Committee of the Lupus Academy, and with the support of the planning staff at Lupus Academy. It has been developed in Joint Providership with Siyemi Learning, an ACCME-accredited provider for CME compliance and certification. No other individuals or organisations have had any influence over the content of this meeting.

Other Educational Activities

The Lupus Academy runs an Annual Meeting and several enduring education initiatives. It also has an extensive library of presentations that is available to registered members, currently free of charge. The Lupus Academy also provides a series of eLearning activities (lupuscme.org) to support its educational goals. From 2019 Lupus Academy has been proud to be the provider of the eLearning course on SLE for the European League Against Rheumatism (EULAR). More information about all Lupus Academy educational activities can be found at lupus-academy.org.

Further Information

The Lupus Academy is a not-for-profit educational foundation with its office in the Netherlands, RSIN 851342097.

Lupus Academy Foundation
Maasdijk 409
4264 AS Veen
The Netherlands

Supporters



LupusAcademy
Communicate. Educate. Treat.

Educational Grant
GSK

14th Annual Meeting | 9-11th October 2025 | Germany



LupusAcademy
Communicate. Educate. Treat.

Sponsorships

Platinum
AstraZeneca, Bristol Myers Squibb


Silver
Viatris

Bronze
AbbVie, Biogen, Galapagos, GSK
Otsuka, UCB

Academy Partner
Janssen, Roche

14th Annual Meeting | 9-11th October 2025 | Germany


Endorsement



EULAR scientific endorsement



Patronage



Under patronage of the German Society of Rheumatology

Financial and in-kind support is only accepted on a strictly “hands-off” basis, where the supporting companies do not have any control or influence over the planning, content, speaker selection or execution of educational activities. Support is received as educational grants, sponsorship, donations or endorsement, and where used, clearly identified.















